

Tests you can trust

November 29, 2025

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited Phiroze Jeejeeboy Towers Dalal Street, Mumbai- 400001 (SCRIP CODE: 539871)

<u>Sub</u>: <u>Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we wish to inform you that Mr. Nitin Chugh, Chief Commercial Officer and part of the Senior Management Personnel of Thyrocare Technologies Limited ("the Company"), has decided to pursue an opportunity outside the organization. He was appointed as Chief Commercial Officer of the Company, forming part of its Senior Management, with effect from February 1, 2024, and will complete his handover and cease to be associated with the Company with effect from the close of business hours on November 30, 2025. We place on record our appreciation for his valuable contributions and wish him the very best in his future endeavours.

The Company has substantially progressed the process of identifying a suitable replacement for the said position. The details will be intimated to the Stock Exchanges in due course, in compliance with applicable laws.

In compliance with Regulation 30 of the SEBI LODR Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, the requisite disclosure is enclosed as **Annexure-1**. The resignation letter submitted by Mr. Nitin Chugh is enclosed as **Annexure-2**.

The above is submitted for your information and records.

Your's faithfully For **Thyrocare Technologies Limited** 

**Brijesh Kumar** 

Company Secretary and Compliance Officer

Encl: A/a

Thyrocare Technologies Limited



## **Annexure-1**

<u>Disclosure under sub-para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (LODR) Regulations, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024</u>

## **Change in Senior Management Personnel**

| 1. | Name & Designation                      | Mr. Nitin Chugh, Chief Commercial Officer  |
|----|---|--|
| 2. | Reason for change viz. appointment,     | Resignation                                |
|    | <del>re-appointment,</del> resignation, |  |
|    | removal, death or otherwise             |  |
| 3. | Date of <del>appointment/re</del>       | With effect from closing of Business hours |
|    | appointment/ cessation (as              | of November 30, 2025                       |
|    | <del>applicable) &amp; term of</del>    |  |
|    | appointment/re-appointment;             |  |
| 4. | Brief Profile (in case of appointment)  | Not Applicable                             |
| 5. | Disclosure of relationships between     | Not Applicable                             |
|    | directors (in case of appointment of    |  |
|    | a director)                             |  |

To Mr. Rahul Guha Managing Director & Chief Executive Officer Thyrocare Technologies Ltd.

Subject: Resignation from the position of Chief Commercial Officer, Thyrocare Technologies Ltd.

Dear Rahul,

As we spoke sometime back, I have decided to step down from my role as Chief Commercial Officer at Thyrocare Technologies Ltd, to pursue a new opportunity outside Company that aligns better with my long-term career aspirations and my last working day will be November 30, 2025, as per the notice period.

This has been a difficult decision, given the meaningful journey I have had here. Over the coming weeks, I am committed to supporting a smooth transition, ensuring effective handovers, knowledge transfer, and continuity for ongoing projects and teams under my charge. Please consider this is my formal notice of resignation submitted on September 01, 2025.

Thanks and regards

Nitin Chugh Emp Id: TSP2414